Agios Pharmaceuticals reported worldwide net revenues of $44.7 million for the second quarter of 2026, up from $12.5 million in the second quarter of 2025, driven primarily by the U.S. commercial launch of AQVESME (mitapivat) for thalassemia. The Cambridge-based biopharmaceutical company narrowed its net loss to $100.7 million from $112.0 million in the prior-year period, supported by robust prescription activity and strategic pipeline advancements including FDA Priority Review for mitapivat in sickle cell disease.

The revenue growth was anchored by strong U.S. performance, where net product revenue reached $40.9 million compared to $12.2 million in Q2 2025. Ex-U.S. net revenue also expanded significantly to $3.8 million from $0.3 million, reflecting anticipated demand for PYRUKYND in Europe following May 2026 approval and consistent early demand in Gulf Cooperation Council countries. As of June 30, 2026, Risk Evaluation and Mitigation Strategy-certified U.S. physicians had written 442 cumulative prescriptions for AQVESME.

Operating expenses rose due to clinical development and commercial scaling efforts. Research and development expenses increased to $100.8 million from $91.9 million in the prior-year quarter, largely driven by a $25.0 million upfront payment for the exclusive global license of cevidoplenib from Oscotec. Selling, general and administrative expenses climbed to $51.5 million from $45.9 million, attributed to activities related to the AQVESME launch. Cost of sales was $3.0 million.

Financial Performance Summary

Pipeline and Strategic Updates

Agios advanced its hematology portfolio through several key milestones. The U.S. Food and Drug Administration granted Priority Review to the supplemental New Drug Application for mitapivat in sickle cell disease, with a Prescription Drug User Fee Act goal date of November 1, 2026. The company also dosed the first patient in the REIGNITE Phase 3 confirmatory trial for this indication. Additionally, Agios licensed cevidoplenib, a spleen tyrosine kinase inhibitor for immune thrombocytopenia, expecting to advance it into Phase 3 development in the first half of 2028.

In its internal pipeline, Agios advanced AG-236 into Phase 2/3 development for polycythemia vera after Phase 1 data demonstrated sustained hepcidin control and potential for every-six-month dosing. Conversely, the company discontinued development of tebapivat in lower-risk myelodysplastic syndromes and sickle cell disease after Phase 2b and Phase 2 trials, respectively, failed to meet predefined thresholds for clinical benefit or differentiation.

What the Numbers Show

The divergence between revenue growth and expense expansion highlights Agios’ transition phase from pure R&D to commercial execution. While revenue more than tripled year-over-year, operating losses remained substantial at $110.6 million, indicating that current product sales are not yet sufficient to offset high development costs. However, the narrowing net loss suggests improving operational efficiency. The company’s cash position of $964.8 million as of June 30, 2026, down from $1.2 billion at year-end 2025, provides adequate runway to fund the AQVESME launch and upcoming pipeline milestones without immediate external capital raises.

Agios Pharmaceuticals Inc. will discontinue development of tebapivat for sickle cell disease after Phase 2 results failed to demonstrate a differentiated profile necessary to support continued investment. The decision impacts the oral pyruvate kinase (PK) activator intended for patients aged 16 years or older, shifting focus away from this specific asset while the company maintains regulatory momentum for a related therapy. The primary endpoint of hemoglobin response was met across dosing arms, yet the data did not distinguish tebapivat sufficiently from other PK activators to warrant further development.

The randomized, double-blind, placebo-controlled trial enrolled 59 participants to evaluate the dose-response relationship of tebapivat. Patients were assigned 2:2:2:1 to receive one of three once-daily doses—2.5 mg, 5.0 mg, or 7.5 mg—or placebo over a 12-week treatment period. Improvements in hemoglobin levels and hemolysis were observed across all active dose levels, consistent with the established PK activation mechanism.

Hemoglobin response, defined as a ≥1.0 g/dL increase in average concentration from Weeks 10 through 12 compared with baseline, was achieved by specific portions of the treatment groups. The 2.5 mg arm saw a 43.8% response rate (n=7/16), the 5.0 mg arm reached 47.1% (n=8/17), and the 7.5 mg arm recorded 29.4% (n=5/17). The placebo arm achieved a 33.3% response rate (n=3/9). Safety and tolerability profiles remained consistent with prior sickle cell disease trials involving the therapy.

Trial Outcomes

Despite the biological activity observed, the trial did not establish the level of differentiation required to justify further resources. Consequently, Agios has determined it will not advance tebapivat in this indication. The company continues to progress its foundational PK activator, mitapivat, for which a supplemental New Drug Application (sNDA) is under FDA Priority Review. The agency has set a PDUFA goal date of November 1, 2026, for that application.